Welcome to our dedicated page for RESMED SEC filings (Ticker: RSMDF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on RESMED's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into RESMED's regulatory disclosures and financial reporting.
RMD reported proposed sales of common stock via Form 144 by an affiliate. The filing lists three separate proposed sales of 1,000 shares each with trade dates 01/02/2026, 02/02/2026, and 03/02/2026, and reported values of $241,750.00, $257,030.00, and $254,300.00 respectively. The filing also lists a prior restricted stock vesting of 1,000 shares with an 11/11/2023 grant date and identifies Fidelity Brokerage Services LLC as the broker.
ResMed Inc. Chairman and CEO Michael J. Farrell exercised options to acquire 4,991 shares of ResMed common stock at $146.34 per share, then sold 4,991 shares at a weighted average price of $251.0322 per share. The filing notes the sale was conducted under a Rule 10b5-1 trading plan adopted on October 31, 2024. After these transactions, he holds 466,223 shares directly and 2,090 shares indirectly through the Lisette and Michael Farrell Family Trust.
RMD filed a Form 144 reporting a proposed sale of 4,991 common shares by Michael Farrell.
The filing states the sale is pursuant to options granted 11/21/2019 and lists the trade date as 03/09/2026 with a cash transaction method. The filing also records two prior sales by the same person: 01/07/2026 (4,991 shares, $1,240,065.36) and 02/09/2026 (4,991 shares, $1,366,436.48).
ResMed Inc. director Peter C. Farrell sold 2,000 shares of ResMed Common Stock in an open-market transaction. The sale occurred on March 4, 2026 at an average price of $260.22 per share. After this trade, he directly owned 62,773 shares. The transaction was conducted under a Rule 10b5-1 trading plan adopted on August 12, 2025.
RMD: Peter C. Farrell reports proposed sale of 2,000 common shares issuable upon exercise of a stock option granted 11/11/2014 (exercise type: Cash). The filing also lists three completed sales of 2,000 common shares each on 12/03/2025, 01/07/2026, and 02/04/2026.
ResMed Inc.'s Chief Financial Officer Brett Sandercock sold 1,000 shares of ResMed common stock in an open‑market transaction at $254.30 per share on March 2, 2026. The sale was executed under a pre‑arranged Rule 10b5‑1 trading plan adopted on February 19, 2025, and he now holds 84,495 shares directly.
RMD filed a Rule 144 notice reporting proposed sales of common stock. The filing lists Fidelity Brokerage Services LLC offering 1,000 shares at $254,300.00 on 03/02/2026. It also discloses recent sales by Brett Sandercock: 1,000 shares on 01/02/2026 for $241,750.00 and 1,000 shares on 02/02/2026 for $257,030.00. The filing notes a 1,000-share restricted stock vesting dated 11/11/2023 described as compensation.
ResMed Inc. Chairman and CEO Michael J. Farrell reported an option exercise and related share sale. On February 9, 2026, he exercised 4,991 ResMed common stock options at an exercise price of $146.34 per share, receiving the same number of common shares.
That same day, he sold 4,991 ResMed common shares in market transactions at a weighted average price of $273.7801 per share under a Rule 10b5-1 trading plan adopted on October 31, 2024. After these transactions, he directly owned 466,223 ResMed common shares and held an additional 2,090 shares indirectly through the Lisette and Michael Farrell Family Trust, along with 44,921 stock options beneficially owned.
ResMed (RMD) insider Michael Farrell has filed to sell common shares under Rule 144. The notice covers 4,991 common shares to be sold through Fidelity Brokerage Services LLC on the NYSE, with an aggregate market value of 1,366,436.43 and 145,678,401 common shares outstanding.
The 4,991 shares were acquired on 02/09/2026 via an option originally granted on 11/21/2019, with the purchase price paid in cash. The filing also lists sales over the prior three months: 4,991 common shares on 12/08/2025 for gross proceeds of 1,254,795.79 and 4,991 common shares on 01/07/2026 for 1,240,065.36.
By signing the notice, the seller represents that he does not know of any undisclosed material adverse information about ResMed’s current or prospective operations.
A shareholder, Peter C Farrell, has filed a notice of intent to sell 2,000 shares of common stock through Merrill Lynch on the NYSE. The planned sale has an aggregate market value of 502540, with 44,448,959 shares of the issuer’s stock reported as outstanding and an approximate sale date of 02/04/2026.
The 2,000 shares were acquired on 11/11/2014 via a stock option transaction for cash. Over the prior three months, Peter C Farrell sold 2,000 shares on each of three dates, with gross proceeds of 504020, 502860, and 497580, indicating a pattern of periodic share sales.